摘要
目的:评价去甲万古霉素与万古霉素治疗耐甲氧西林葡萄球菌感染的成本—效果。方法:选择临床确诊为耐甲氧西林葡萄球菌(MRS)感染的45例病例,随机分成两组,一组22例为去甲万古霉素治疗组,一组23例为万古霉素治疗作为对照组,对其疗效及药物费用进行分析。结果:去甲万古霉素、万古霉素临床有效率分别为81.8%、82.6%(P>0.05),细菌学清除率分别为86.4%、87.0%(P>0.05)。而去甲万古霉素组平均药物费用小于万古霉素组,分别为(2325±386.2)元和(4483±643.7)元(P<0.05)。结论:去甲万古霉素组的临床有效率、细菌学清除率与万古霉素组相比差异无统计学意义,但治疗药物费用比万古霉素低。
Objective： To compare the cost and outcomes of norvancomycin and vancomycin in the treatment for MRS in patients. Methods. 45 patients who were diagnosed as MRS infection were randomly enrolled into norvancomycin group （ n = 22） and vancomycin group （ n = 23）. The effectiveness and drug cost between the two group were analyzed. Results： The rates of clinical effectiveness of norvancomycin group and vancomycin group were 81.8% and 82.6% respectively （P〉0.05）, the bacterial clearances rate of the two group were 86.4% and 87.0% respectively （P〉0.05）. The mean drug cost per patient in norvancomycin treated group was lower than that in vancomycin treated group （2325 ± 386.2） RMB vs. （4483 ± 643.7） RMB （ P 〈 0.05）. Conclusion： The clinical effectiveness of norvancomycin have no difference with vancomycin, but its cost - effectiveness is better.
出处
《现代预防医学》
CAS
北大核心
2006年第8期1476-1477,共2页
Modern Preventive Medicine
